XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q3 2026 | — | -0.69 | — | $659,848 | — | +5.01% | -12.72% | +117.51% |
| 2026-02-11 | Q2 2026 | — | -0.51 | — | $820,188 | — | -11.11% | -13.23% | -22.12% |
| 2025-11-06 |
| Q1 2026 |
| — |
| -0.44 |
| — |
| $1.1M |
| — |
| — |
| — |
| — |
| 2025-09-23 | Q4 2025 | — | -0.43 | — | $1.3M | — | — | — | — |
| 2025-02-12 | Q2 2025 | — | -3.64 | — | $1.1M | — | -3.13% | +4.06% | -11.88% |
| 2024-11-14 | Q1 2025 | — | -2.71 | — | $1.3M | — | -15.73% | -8.46% | +2.17% |
| 2024-09-30 | Q4 2024 | — | -3.80 | — | $1.3M | — | -6.33% | -9.28% | +23.59% |
| 2024-05-14 | Q3 2024 | — | -3.60 | — | $1.2M | — | +2.62% | +23.30% | -11.05% |
Showing last 8 quarters.